3692 — Hansoh Pharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$192.43bn
- HK$153.55bn
- CNY15.03bn
Brief: Hansoh Pharmaceutical Says Risvutatug Rezetecan Injection Included In NMPA Priority Review
Brief: Hansoh Pharmaceutical Says NMPA Accepts Biologics License Application Of HS-20093
China's Hansoh Pharmaceutical jumps most on record on H1 profit growth
China's Hansoh Pharma posts 36% rise in first-half profit helped by innovative drug sales (updated)
Hansoh Pharma reports near 36% rise in first-half profit
China's Hansoh Pharma H1 revenue rises, driven by innovative medicines segment
Brief: Hansoh Pharmaceutical Says Clinical Trial Approval For HS-10582 Tablets
Brief: Hansoh Pharmaceutical Says Phase III Clinical Study Of HS-20093 Has Met Primary Endpoint
GSK, Hansoh's bone cancer drug meets main goal in late-stage trial (updated)
Hansoh Pharma says osteosarcoma treatment drug meets primary endpoint in late stage trial
Brief: Hansoh Pharmaceutical Discloses Transactions With Avere Therapeutics
Brief: Hansoh Pharmaceutical Says HS-20,093 Meets Primary Endpoint In Phase III SCLC Trial
GSK, Hansoh's targeted cancer drug hits main survival goal in China trial (updated)
GSK's targeted cancer therapy shows positive results in late-stage study
Factbox: Race to launch weight-loss pills heats up as smaller players advance
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Hansoh Pharmaceutical Says Clinical Trial Approvals For HS-20136-2 Injection Issued- By NMPA
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Race to launch weight-loss pill heats up as Novo wins UK approval